Orexigen Therapeutics (OREX) Defended at Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Buy This Dip in Orexigen (OREX), RBC Capital Says
May 13, 2015 6:35 AM EDTRBC Capital analyst Simos Simeonidis said with everyone pilling on against Orexigen Therapeutics (NASDAQ: OREX) they are buyers on this dip. The firm reiterated an Outperform rating and price target of $14.00.
Simeonidis said they spoke with CEO, Mike Narachi, who told them he "adamantly refutes the assertions that the company misled investors and patients." He was defiant in regards to today's news and defended Orexigen's handling of the LIGHT trial data. He told us that there was a data access plan in place, it was followed, and it actually had provisions for... More
Orexigen (OREX) Comments on Light Study Termination; Takeda Initiated Formal Dispute Process
May 13, 2015 6:05 AM EDTOrexigen Therapeutics (NASDAQ: OREX) issued the following statement regarding the termination of the Light Study a cardiovascular (CV) outcomes trial that compared the obesity drug Contrave® (naltrexone HCI and bupropion HCl extended-release tablets) to placebo, in addition to diet and exercise counselling, in 8,909 overweight and obese patients with certain CV risk factors, and an update on its Contrave collaboration with Takeda Pharmaceuticals Company.
This morning (Tuesday morning) we and Takeda announced termination of the Light Study. We agreed with our partner, and together discussed our preferences with the U.S. Food and... More
UPDATE: Orexigen Therapeutics (OREX) and Takeda in Arbitration Over Terms of Deal
May 12, 2015 4:25 PM EDT(Updated - May 12, 2015 4:27 PM EDT)
Orexigen Therapeutics (NASDAQ: OREX) and Takeda are in arbitration on terms of collaboration, the company's CEO says in Bank of America presentation, according to CNBC's Meg Tirrell.
... More
Orexigen Therapeutics (OREX) Mentioned Cautiously at Forbes
May 12, 2015 11:20 AM EDTOrexigen Therapeutics (NASDAQ: OREX) was mentioned cautiously in a Forbes article discussing results of its Light study of Contrave (link here).
... MoreLight Study Termination 'Positive' for Orexigen (OREX), Leerink Partners Says
May 12, 2015 9:51 AM EDTLeerink Partners Paul Matteis said the termination of the Light Study by Orexigen Therapeutics (NASDAQ: OREX) and partner Takeda is a "positive."
"The stopping of the study is not due to any finding of superiority or harm. We believe the termination... More
Takeda, Orexigen Therapeutics (OREX) Announce Early Termination of Light Study
May 12, 2015 8:34 AM EDTTakeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Development Center Americas, Inc. (Takeda) and Orexigen Therapeutics, Inc. (Nasdaq: OREX) (Orexigen) have accepted the recommendation of the Executive Steering Committee (ESC), chaired by Dr. Steven Nissen of The Cleveland Clinic, for early termination of the Light Study, a... More
